2019 Chem-Reaxys 学术周
10月14日 - 南开大学
10月16日 - 南京大学
10月18日 - 华南理工大学
本次学术周由Chem杂志主编，著名国际学术期刊出版人Dr. Robert Eagling担任主席，活动分为三场，分别于南开大学，南京大学和华南理工大学举办。来自美国芝加哥大学的Guangbin Dong教授，美国威斯康辛大学的Jennifer M. Schomaker教授和德国明斯特大学的Armido Studer教授将作为国际主讲嘉宾全程出席。美国默沙东的高级副总裁Dr. Michael H. Kress 也将和参会者分享医药研发领域的创新性研究。南开大学的崔春明教授，南京大学的朱成建教授和华南理工大学的江焕峰教授应邀担任三场分会主席。每场分会将由主席另外邀请5-10位中国有机化学家做主题演讲。
为支持女性在化学科学领域的发展，此次学术周活动首次设立了女性化学论坛环节(Women in Chemistry Seminar)。 多位来自高校及医药行业的资深女性科学家将带来科学报告，专题报告，以及互动讨论环节。其中，来自美国默沙东的副总裁Dr. Caroline McGregor将在10月14日南开大学场带来“Hidden Diversity: A personal reflection on diversity & Inclusion”的专题报告。美国默沙东的执行总监Ms. Marguerite Mohan将在南京大学及华南理工大学场带来专题报告。在互动讨论环节中，女化学家们还将与参会者进行职业选择和个人发展经验分享，并就化学科研领域的性别发展不均衡，如何能更好支持鼓励女性化学工作者发挥自身潜能，参与科研创新等热点问题进行讨论。参加女性化学论坛的嘉宾包括：中国科学院理化技术研究所的吴骊珠教授，南开大学的渠瑾教授，美国默沙东的Dr. Caroline McGregor, Ms. Marguerite Mohan, Dr. Jing Xu, 南京大学的祝艳教授，鲁艺教授，南方科技大学的汪君教授和中山大学的张利教授，爱思唯尔大中华区市场总监朱宇红女士等。
Professor of Chemistry, The University of Chicago
Dr. Guangbin Dong received his B.S. degree from Peking University and completed his Ph.D. degree in Chemistry from Stanford University with Professor Barry M. Trost. In 2009, He joined the group of Prof. Robert H. Grubbs at California Institute of Technology, as a postdoctoral researcher. His expertise is in the field of organic synthesis, catalysis, organometallics and medicinal chemistry. His future research interests lie at the development of powerful chemical tools for addressing questions of biological importance. His research program will bring together the complimentary knowledge of organic synthesis, medicinal chemistry and organometallic chemistry in collaboration with scientists in the field of cellular biology and animal pharmacology to identify effective small-molecule agents that target new molecular mechanisms for cancer treatment.
View full bio
Dr. Dong’s Ph.D. research studies involved development of new catalytic enantioselective synthetic methods and applied these methods in the total syntheses of biologically important molecules. The majority of the natural products Dr. Dong synthesized exhibit high potent anticancer activity, such as agelastatin A, terpestacin, and bryostatins. In addition, he has designed and synthesized a new bryostatin analogue; in collaboration with Genetech, this agent has show nanomolar anticancer activity again several cancer cell lines. This work has been published in Nature.
At California Institute of Technology, Dr Dong was a Camille and Henry Dreyfus Environmental Chemistry Fellow in the group of Professor Robert H. Grubbs. His research aimed at development of catalysts for anti-Markovnikov hydration of olefins, considered as one of the top 10 challenges in catalysis. Dr. Dong developed the first reproducible anti-Markovnikov olefin hydration process using a dual-metal system.
Dr. Dong's primary goal as an advisor is to give graduate students and postdocs with professional training that will assist them for their future careers as independent researchers. He will create a healthy environment where both students and postdocs are able to share experiences and knowledge with each other. The key is to offer each group member sufficient freedom to explore on his/her own. They should be allowed to make their own mistakes and correct themselves by finding their own solutions. They will be encouraged to talk more to each other and learn from each other. Meanwhile, he will be around and ready to give suggestions. Dr. Dong believe that such a collaborative environment would be beneficial for students and postdocs to develop into thoughtful scientists capable of conducting research on an independent level.
Jennifer M Schomaker
Professor of Chemistry, The University of Wisconsin-Madison
Professor Schomaker began her research career at Dow Chemical in Organic Chemicals and Polymers, later moving to Agricultural Chemicals Process Research, where she participated in the route selection and scale-up campaigns for two new herbicides. After nearly 7 years in industry, she returned to academia, obtaining her Ph.D. with Professor Babak Borhan at Michigan State University in 2006 before moving to UC-Berkeley as an NIH postdoctoral fellow in the labs of Professors Robert G. Bergman and F. Dean Toste.
View full bio
She joined the faculty at the University of Wisconsin-Madison in 2009, where her research focuses on new methodologies for the preparation of stereochemically complex, densely functionalized amines, catalyst-controlled, tunable chemo- and site-selective C-H functionalizations, uncovering new reactivities catalyzed by first-row transition metals, the total synthesis of bioactive natural and unnatural products, and development of new bioorthogonal labeling reagents. Her awards include the NSF-CAREER, Sloan Research Fellowship, Thieme Chemistry Journal Award, ACS-WCC Rising Star Award, ACS DOC Early Academic Investigator Award, MSU Distinguished Alumni Award, and UW-Vilas Mid-Career and UW2020 Awards. She was named a Kavli Fellow and recently received a Gabor A. and Judith K. Somorjai Visiting Miller Professorship Award from UC-Berkeley.
Professor of Organic Chemistry, Westfälische Wilhelms-Universität Münster
Professor Armido Studer studied chemistry at the ETH Zürich, Switzerland, and gained his Ph.D. from there in 1995, under the guidance of Professor Dieter Seebach. From 1995–1996, he performed postdoctoral studies at the University of Pittsburgh, USA, in the group of Professor Dennis Curran. Studer did his Habilitation at the Laboratory of Organic Chemistry, ETH Zürich, on the development of new synthetic methods in the field of free radical chemistry.
View full bio
In 2000, he was appointed Associate Professor of Organic Chemistry at the Philipps-Universität Marburg, Germany, and in 2004, as Full Professor (C4) of Organic Chemistry at the Westfälische Wilhelms-Universität Münster, Germany.
Since 2009, he has been Full Professor (W3) of Organic Chemistry at the Westfälische Wilhelms-Universität Münster.
Michael H. Kress
Senior Vice President, Process Research and Development, MSD
Dr. Kress received his B.S. in Chemistry from the Pennsylvania State University. Upon graduation Mike joined the laboratory of Professor Yoshito Kishi at Harvard, where his research focused on the total synthesis of members of the taxane diterpene family. Upon receiving his Ph.D. Mike accepted the position of Sr. Research Chemist within the MSD Process Research group where his research focused on the development of efficient synthetic processes to a variety of drug development targets within MSD's diabetes (PPAR) and pain franchises (BK-1, Nav-1.7).
View full bio
In 2006 Mike accepted the position of Senior Director of Worldwide Process Research at Cephalon, Inc. While at Cephalon, Mike’s research interests were focused on the enantioselective Kagan oxidation of prochiral sulfides, and efficient manufacturing routes to stuarosporin-like PKC inhibitors.
Mike returned to MSD as Executive Director of Pharmaceutical Development in 2007, and was promoted to the position of Vice President of Pharmaceutical Research and development in early 2008. During his tenure within drug product development Mike collaborated to support a number of key development programs and product launches, including: Janumet XR, Belsomra, Zepatier.
In 2013 Mike accepted the position of Vice President of MSD’s small molecule Process Research and Development (PRD) team, and in 2018 was promoted into his current role to lead Process Research and Development activities across the small molecule, biologics and vaccines modalities. Mike is a member of the American Chemical Society, the American Association of Pharmaceutical Scientists, and the Innovation and Quality Consortia.